North American Report

Marburg Virus Disease Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | BioCryst Pharmaceuticals, Bavarian Nordic, Flow Pharma, Public Health Vaccines and Others

 Breaking News
  • No posts were found

Marburg Virus Disease Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | BioCryst Pharmaceuticals, Bavarian Nordic, Flow Pharma, Public Health Vaccines and Others

May 28
22:14 2021
Marburg Virus Disease Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | BioCryst Pharmaceuticals, Bavarian Nordic, Flow Pharma, Public Health Vaccines and Others

Marburg Virus Disease Pipeline

Marburg virus was first recognized in 1967, when outbreaks of hemorrhagic fever occurred simultaneously in laboratories in Marburg and Frankfurt, Germany and in Belgrade, Yugoslavia (now Serbia). Marburg hemorrhagic fever (Marburg HF) is a rare but severe hemorrhagic fever which affects both humans and non-human primates. Marburg HF is caused by Marburg virus, a genetically unique zoonotic (or, animal-borne) RNA virus of the filovirus family.

Signs and Symptoms

After an incubation period of 5-10 days, symptom onset is sudden and marked by fever, chills, headache, and myalgia. Around the fifth day after the onset of symptoms, a maculopapular rash, most prominent on the trunk (chest, back, stomach), may occur. Nausea, vomiting, chest pain, a sore throat, abdominal pain, and diarrhea may then appear.

Symptoms become increasingly severe and can include jaundice, inflammation of the pancreas, severe weight loss, delirium, shock, liver failure, massive hemorrhaging, and multi-organ dysfunction.

 

DelveInsight’s, Marburg Virus Disease Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Marburg Virus Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Some of the Marburg Virus Disease Companies are:

  • BioCryst Pharmaceuticals
  • Bavarian Nordic
  • Flow Pharma
  • Public Health Vaccines
  • AlphaVax
  • Emergex Vaccines
  • ReiThera
  • Globavir Biosciences
  • Mapp Biopharmaceutical
  • And Many Others

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/marburg-virus-disease-pipeline-insight

 

DelveInsight’s Marburg Virus Disease report covers around 6+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Some of the Marburg Virus Disease Therapies are:

  • MVA-BN filovirus vaccine
  • Galidesivir
  • And Many Others

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/marburg-virus-disease-pipeline-insight

 

Current  Marburg Virus Disease Treatment Scenario and  Marburg Virus Disease Emerging Therapies:

  • How many companies are developing Marburg Virus Disease drugs?
  • How many Marburg Virus Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Marburg Virus Disease?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Marburg Virus Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Marburg Virus Disease and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/marburg-virus-disease-pipeline-insight

 

Table of Contents:

Introduction

Executive Summary

Marburg Virus Disease: Overview

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

Marburg Virus Disease – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Mid Stage Products (Phase II)

  • Comparative Analysis

MVA-BN filovirus vaccine: Bavarian Nordic

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

Galidesivir: BioCryst Pharmaceuticals

Drug profiles in the detailed report…..

Inactive Products

Marburg Virus Disease Key Companies

Marburg Virus Disease Key Products

Marburg Virus Disease- Unmet Needs

Marburg Virus Disease- Market Drivers and Barriers

Marburg Virus Disease- Future Perspectives and Conclusion

Marburg Virus Disease Analyst Views

Marburg Virus Disease Key Companies

Appendix

Request for Detailed TOC: https://www.delveinsight.com/sample-request/marburg-virus-disease-pipeline-insight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/marburg-virus-disease-pipeline-insight